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a b s t r a c t
This study characterized the extent and patterns of self-reported drug use among aging adults with
and without HIV, assessed differences in patterns by HIV status, and examined pattern correlates. Data
derived from 6351 HIV-infected and uninfected adults enrolled in an eight-site matched cohort, the
Veterans Aging Cohort Study (VACS). Using clinical variables from electronic medical records and sociodemographics, drug use consequences, and frequency of drug use from baseline surveys, we performed
latent class analyses (LCA) stratiﬁed by HIV status and adjusted for clinical and socio-demographic covariates. Participants were, on average, age 50 (range 22–86), primarily male (95%) and African-American
(64%). Five distinct patterns emerged: non-users, past primarily marijuana users, past multidrug users,
current high consequence multidrug users, and current low consequence primarily marijuana users.
HIV status strongly inﬂuenced class membership. Non-users were most prevalent among HIV uninfected
(36.4%) and current high consequence multidrug users (25.5%) were most prevalent among HIV-infected.
While problems of obesity marked those not currently using drugs, current users experienced higher
prevalences of medical or mental health disorders. Multimorbidity was highest among past and current multidrug users. HIV-infected participants were more likely than HIV-uninfected participants to be
current low consequence primarily marijuana users. In this sample, active drug use and abuse were common. HIV-infected and uninfected Veterans differed on extent and patterns of drug use and on important
characteristics within identiﬁed classes. Findings have the potential to inform screening and intervention
efforts in aging drug users with and without HIV.
© 2010 Elsevier Ireland Ltd. All rights reserved.

1. Introduction

夽 A summary table of the results is available with the online version of this article.
Please see Appendix A at doi:10.1016/j.drugalcdep.2010.02.020.
夽夽 Disclaimer: The views expressed in this article are those of the authors and do
not necessarily reﬂect the position or policy of the Department of Veterans Affairs.
∗ Corresponding author at: 111 Plain St. Building, Rm 111, Providence, RI 02903,
USA. Tel.: +1 401 444 3845; fax: +1 401 444 5040.
E-mail address: traci.c.green@brown.edu (T.C. Green).
0376-8716/$ – see front matter © 2010 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.drugalcdep.2010.02.020

Drug use among older adults in the US is occurring at unprecedented high levels and growing. The baby boom generation (i.e.,
people born 1946–1964) has higher prevalences of lifetime drug
use compared to all previous generations and appears to be continuing their drug use later into life (Han et al., 2009a). In 2007, all
adults aged 50–59 were baby boomers; recent national data reveal
that in the same year the prevalence of self-reported past year illicit
drug use in this age group nearly doubled from 2002 ﬁgures (Han
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et al., 2009b). Updated projections forecast that by 2020, the number of adults 50 or older with substance use disorder will more
than double from 2.8 million in 2002–2006 to 5.7 million (Han
et al., 2009b), a projection 30% higher than previously estimated
(Colliver et al., 2006; Gfroerer et al., 2003). The enormity of this
problem is compounded by under-recognition of substance use in
older people (Levin and Kruger, 2002), limited data on the types
and patterns of their drug use (Levy, 1998; Lieberman, 2000), the
lack of substance abuse treatment services for older adults (Ofﬁce
of Applied Studies, 2007), under-utilization of screening tools for
primary care practitioners to identify substance abuse problems
(Friedmann et al., 2001; Kim et al., 2007; Lewis, 1997), and the
medical and psychological comorbidities that often accompany and
complicate the health status of older drug users (Geriatric Mental
Health Foundation, 2010; Reid and Anderson, 1997; Reid et al.,
2002; Simoni-Wastila and Yang, 2006).
At the same time, HIV is increasingly affecting older populations because HIV-infected persons are living longer on more
effective treatments while HIV incidence in this age group is on
the rise. Approximately 10% of new HIV infections in the US occur
among people over 50 years of age (Centers for Disease Control
and Prevention, 2008). Drug use, especially by injection, is one of
the primary modes of HIV and hepatitis transmission, and thus one
might expect HIV-infected older adults to have higher prevalences
of injection drug use (IDU) compared to their uninfected peers. On
the other hand, HIV incidence among IDUs has declined by 50% or
greater over the past 20 years (Des Jarlais et al., 2000; Lee et al.,
2003), and, in many places, HIV transmission among IDUs has been
associated with sexual transmission rather than unsafe injection
(Centers for Disease Control and Prevention, 2009; Kral et al., 2001;
Strathdee et al., 2001). Furthermore, most illicit drug use in the
US is non-injection (Substance Abuse and Mental Health Services
Administration, 2009). Regardless of HIV status and transmission
category, patterns of current drug use are poorly understood in
older adults (Rabkin et al., 2004; Rosenberg, 1995; Schlaerth, 2007).
The nexus of these three issues – drug use, HIV, and aging – is
an understudied yet looming problem. Evidence suggests that HIV
may speed aging and exacerbate problems of older age. Active drug
use contributes to poor health outcomes for people with and without HIV alike (AETC, 2006; Bruce et al., 2008; Kapadia et al., 2005),
and may be particularly harmful if addictive disorders persist later
in life. Older adults with HIV may thus be disproportionately burdened by the negative consequences of ongoing drug abuse (Zanjani
et al., 2007). For example, both older age and HIV infection are
risk factors for unintentional fatal drug overdose (Darke and Zador,
1996; Tardiff et al., 1997; Wang et al., 2005). Biological mechanisms
of this elevated risk may be due to changes in metabolism and body
water content in older adults that can lead to higher serum drug
concentrations over prolonged periods, thereby increasing risks of
unintentional injuries such as drug overdose.
Few studies have been conducted with sufﬁcient power to
contrast drug use by HIV status and age; even fewer provide generalizable data (Levy, 1998; Lieberman, 2000) or detailed information
regarding medical and psychiatric comorbidities related to substance use problems. One study, limited by sample size, found that
lifetime drug dependence was higher for the HIV-infected than
uninfected individuals, and that expected age-associated declines
in diagnoses of dependence were not detected among the HIVinfected (Rabkin et al., 2004). Analysis of data from a larger, more
diverse sample is needed to assist clinicians and policy makers in
developing evidence-based responses to changing patterns of drug
use in aging populations.
In this paper, we used data from the Veterans Aging Cohort Study
(VACS) (Justice et al., 2006a), a longitudinal, prospectively consented, observational cohort study conducted among HIV-infected
Veterans and age-, race- and site-matched HIV uninfected controls

209

receiving medical care at one of eight US Veterans Administration (VA) facilities to: (1) characterize patterns of self-reported
drug use in a large and diverse cohort of aging HIV-infected and
uninfected US Veterans and analyze their construct validity; (2)
assess pattern differences by HIV status; and (3) describe demographic, medical and psychiatric pattern correlates within this
population. To accomplish these aims, we employed latent class
analysis (LCA) (Agrawal et al., 2007; Lubke and Muthen, 2005;
Muthen, 2006) to identify patterns of behavior, using all available
baseline VACS information. We chose this empirical approach to
minimize the potential for measurement error, bias, or oversimpliﬁcation (Kapadia et al., 2005) inherent when a priori deﬁnitions are
used to aggregate and categorize complex behaviors.
2. Methods
2.1. Sample
VACS has been described extensively elsewhere (Conigliaro et
al., 2004; Justice, 2006; Justice et al., 2006a,b, 2001); design and
population characteristics pertinent to this analysis are reported
here. Initiated in 2002, the eight-site VACS aimed to explore comorbidities and behaviors affecting medical outcomes in the broader
context of aging and HIV (Justice et al., 2006a, 2001). HIV-infected
participants were recruited from VA infectious disease clinics;
uninfected participants were recruited from VA general medicine
clinics. Participants are largely male, representative of the VA population in care for HIV (Justice et al., 2006a). VACS is characterized
by a network of administrative, clinical, and research resources that
allows linkage of annual self-reported survey data to electronic
medical records (EMR), vital statistics, pharmacy prescriptions, and
healthcare use. Annual loss to follow up is <5%.
2.2. Measures
2.2.1. Drug use and consequences. The VACS baseline survey
included items on frequency of use (Centers for Disease Control
and Prevention, 2002) of marijuana, heroin/opioids, cocaine/crack,
and stimulants (amphetamines, speed, crystal methamphetamine).
Responses for marijuana and stimulant/cocaine use were: never,
no use in the past year, some use in the past year (monthly or
less often), and heavy use in the past year (weekly to daily use).
For heroin/opioids the response options were never, not in the
past year, any past year use. Due to sparseness of data and lack
of clinically meaningful differences in their use, stimulant use was
grouped with cocaine/crack use. The degree of consequence (high,
low) experienced due to drug use was derived from an item within
the Michigan Composite International Diagnostic Interview (CIDISF) (Kessler et al., 1998): “In the past 12 months, did your use of
drugs ever interfere with your work at school, or a job, or at home?”
Responses were never drug use, use more than 1 year ago (problems
may or may not have been experienced), no problems experienced
in the past year, or problems experienced in the past year. Together,
these items comprised the indicators for the LCA.
2.2.2. Covariates. Variables known to be associated with drug use
that might differentiate the patterns included socio-demographics,
comorbidities (hepatitis C (HCV), medical and psychiatric conditions) (Kilbourne et al., 2001), history of and past year injection drug
use, and past year receipt of VA substance abuse and mental health
treatment. The selection of candidate covariates of the LCA was
a theoretically driven one that was tested statistically in the LCA.
The theoretical model informing our analyses was Gelberg’s Behavioral Model for Vulnerable Populations, which amends Andersen’s
Behavioral Model to explicitly include domains especially relevant to vulnerable populations (e.g., the homeless) to explain and
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predict personal health practices (Gelberg et al., 2000). In this
model, health outcomes and behaviors are functions of predisposing factors, enabling resources, and need. Predisposing domains
traditionally include demographics like age, gender, and ethnicity,
but were expanded to include vulnerable domains such as lifestyle
instability. In this analysis, we considered HIV positive Veterans as
a vulnerable population. Substance abuse, race/ethnicity, and gender are conceptualized as predisposing factors; enabling resources
include having a regular care provider, HAART, and income; need
encompasses health status, presence of depressive symptoms, and
comorbidities; health behaviors act as intermediate outcomes and
include adherence to medication; and outcomes are disease progression and death. The focus of the present analysis is on the
interplay of predisposing, enabling, and need factors as covariates of the LCA; the remaining domains are the subject of future
analyses. Socio-demographics included age, race/ethnicity, education level, income, marital status, smoking, body mass index
((BMI) calculated based on self-reported height and weight) and
having ever been homeless or marginally housed. Current problem drinking was assessed by the AUDIT-C (Bush et al., 1998).
Other covariates included lifestyle instability (Gordon et al., 2006;
Kim et al., 2006; McFarland et al., 2003; Shapiro et al., 1999;
Song et al., 2000), approximated by past month homelessness and
concern about food availability, and quality of life (mental, physical composite scores) which was captured by the Short Form-12
(SF-12) (Ware et al., 1996). Comorbidities were identiﬁed using
International Classiﬁcation of Diseases, 9th revision (ICD-9-CM)
codes from the participant’s EMR, grouped into clusters of medical
and psychiatric disease diagnoses, as previously reported (Goulet
et al., 2005, 2007). For participants with HIV, concurrent AIDSassociated illness occurring 1 year before and 6 months after
baseline was deﬁned according to the Centers for Disease Control
and Prevention’s (1993) case deﬁnition.
2.3. Analysis
2.3.1. Overview. We used LCA, a statistical method for creating
meaningful subgroups, or latent classes, based on similarities in
responses to a set of observed indicators. It is assumed that the
observed variables are independent from one another once conditioned on the latent variable, an assumption known as local
independence (Hagenaars and McCutcheon, 2002). LCA produces:
(a) the prevalence of each latent class (i.e., prior probability that a
randomly chosen person will be in each class) and (b) the probability of response to an indicator, conditional on the latent class. Class
categorizations are based on the prevalence of the latent classes and
are mutually exclusive and exhaustive. While an individual has a
probability of membership in all of the latent classes, theoretically,
they belong to one true class. Based on the proﬁle of the response
indicators, a putative name for the class can be derived. LCA has
a number of advantages. It can incorporate covariates that may
inﬂuence class membership (Muthen, 2004). LCA has been used
previously in evaluations of subjects with substance use disorders
(e.g., Monga et al., 2007). Also, LCA employs a full information maximum likelihood approach that allows for analysis of all available
data, assuming data are missing at random. Therefore we were able
to model using all available baseline cases instead of deleting those
with missing drug use data.

quality (Muthen and Muthen, 2007), and yield interpretable latent
classes of >1% prevalence. Once a ﬁnal model was selected, we
tested for differences by HIV status and then incorporated covariates in an adjusted LCA model. Results describe the empirically
derived classes and their construct validity. Mplus version 5.1 software (Muthen and Muthen, 2007) was used to ﬁt LCA models.
2.3.3. Construct validity. Adjusted latent classes were compared
to other classiﬁcations of drug abuse and dependence obtainable
through medical records and VACS surveys. These included, respectively, ICD-9-CM diagnoses and CIDI-SF score ≥4, indicating high
probability of fulﬁlling DSM-IV drug dependence criteria (Kessler
et al., 1998; Robins et al., 1988). A search of the participant’s EMR
1 year prior and 6 months after the survey visit date was conducted of VA administrative records at the Austin Automation
Center (Austin, TX) for ICD-9-CM diagnosis codes 291.00–292.99
and 303.00–305.99 (Druss and Rosenheck, 2000). Patients were
coded dichotomously according to whether or not their EMR noted
abuse and/or dependence of alcohol or drugs. Using 2 and Kappa
statistics, we assessed how these related indicators mapped onto
the derived latent classes (Orlando et al., 2004, 2005; Tucker et al.,
2006) as “validating indicators”.
2.3.4. Differences by HIV status. By including HIV status as a covariate that could have class-varying probabilities and comparing the
ﬁt of nested models (Muthen and Muthen, 2007) using 2 tests
we assessed for differences by HIV status. Direct effects (i.e., HIV
effects drug use indicators directly versus through the latent class)
were tested in similar fashion. Based on these results, subsequent
LCA analyses were stratiﬁed by HIV status, to characterize diseasespeciﬁc class differences and correlates.
2.3.5. Adjusting for covariates. To examine correlates of class membership, we conducted latent class regression. We adjusted for
covariates by employing a stepped modeling approach (Delucchi et
al., 2004). First, taking the modal predicted most likely class from
the unadjusted LCA as the outcome, class-speciﬁc differences were
tested for all covariates using bivariate analyses (Wald 2 tests for
categorical variables, ANOVAs or Kruskall–Wallace test for continuous variables), stratiﬁed by HIV status. Due to the large number of
comparisons made, the overall ˛ level was Bonferroni-corrected
to p < .0013 (˛ = .05/39). Variables found to be signiﬁcant were
then entered into a multinomial logistic regression of the modal
predicted most likely class to determine factors independently
associated with membership (Ghandour et al., 2008). The resulting
signiﬁcant covariates were considered candidates for the adjusted
latent class regression model. Then, HIV-speciﬁc LCAs were reestimated incorporating the candidate variables and checking that
covariates excluded earlier in the analysis did not signiﬁcantly
improve ﬁt, reduce variance, or measurably (≥10%) alter parameter
estimates. Last, by testing nested models, any candidate variables
that did not help differentiate classes were dropped from the ﬁnal
adjusted latent class regression models. Results present the classand HIV-speciﬁc socio-demographic and health status variables.
This study was approved by institutional review boards at the Yale
School of Medicine and the VA Connecticut Healthcare System,
West Haven.
3. Results

2.3.2. Modeling approach. First, we constructed a LCA model using
the entire sample (regardless of HIV status). We systematically
built from simple unadjusted to more complex adjusted models.
Unadjusted models considered one to seven classes. To identify
the optimal number of latent classes and the best ﬁtting model,
we sought to minimize the Bayesian Information Criteria (BIC),
maximize entropy, a summary measure that conveys classiﬁcation

3.1. Study sample
Participants were, on average, age 50 (range 22–86), primarily male and African–American (Table 1). HIV-infected participants
were signiﬁcantly more likely to be African–American, HCV
seropositive, not married or living with a partner, and to have
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Table 1
Characteristics of the HIV-infected (n = 3160) and HIV uninfected (n = 3191) VACS participants.
HIV−

HIV+

p-value

N

%

N

%

Age, mean (SD)
Vietnam era cohort†
Male
Race White
African–American
Hispanic
Other

3191
2016
2938
782
1974
320
115

50.7 (10.0)
63.2
92.1
24.5
61.9
10.0
3.6

3160
1881
3080
637
2103
297
123

49.4 (8.8)
59.5
97.5
20.2
66.5
9.4
3.9

<.0001
.003
<.0001
0.002

Education < high school
Ever homeless
Homelessness, past month
Married/living with partner
Annual income >$25,000

1294
1337
380
1240
1046

41.0
41.9
11.9
39.1
32.8

1276
1515
256
711
747

40.7
47.9
8.1
22.8
23.6

.79
<.0001
<.0001
<.0001
<.0001

BMI categories Obese
Overweight
Normal
Underweight

1242
1186
702
39

39.2
37.4
22.1
1.2

407
1146
1457
123

13.0
36.6
46.5
3.9

<.0001
0.49
<.0001
<.0001

Smokes currently
Mean (SD) SF-12 composite score Mental
Physical
HCV+
Medical disease cluster
Diabetes
Hypertension
Renal disease
Pulmonary disease
Liver disease (not including hepatitis)
Vascular disease

1394
3169
3181
767
2236
730
1705
90
365
29
473

44.1
47.5 (11.8)
42.2 (11.4)
24.0
70.1
22.9
53.4
2.8
11.4
0.9
14.8

1656
3149
3148
1474
1879
402
944
120
285
59
252

52.6
46.7 (11.2)
43.5 (10.6)
46.6
59.5
12.7
29.9
3.8
9.0
1.9
8.0

<.0001
0.004
<.0001
<.0001
<.0001
<.0001
<.0001
.003
.001
.001
<.0001

Psychiatric disease cluster
Schizophrenia
Major depression, bipolar
Post traumatic stress disorder
Medical & psychiatric disease cluster‡

880
210
569
407
655

27.6
6.6
17.8
12.7
20.5

738
134
539
247
530

23.3
4.2
17.1
7.8
16.8

<.0001
<.0001
.41
<.0001
<.0001

Past year treatment Substance abuse
Methadone maintenance
Mental health

536
159
1166

16.8
5.0
36.5

449
144
926

14.2
4.6
29.3

0.004
0.41
<.0001

IVD past year
Alcohol use past year
AUDIT-C score (mean, SD)
Problem drinking cutoff+

137
2031
3084
995

4.3
67.4
2.7 (2.9)
31.2

7.4
68.4
2.6 (2.6)
28.8

<.0001
0.39
0.014
0.041

ICD-9 baseline diagnosis* : Alcohol abuse/dependence
Drug abuse/dependence
CIDI-SF deﬁned drug dependent*
AIDS-associated illnesses, past year

740
799
409
–

231
2048
3026
911

23.2
25.0
13.5

586
793
449

18.5
25.1
14.9

<.0001
0.96
0.14

–

707

22.4

NA

AUDIT-C = alcohol use disorders identiﬁcation test-consumption, BMI = body mass index, ICD-9 = International Classiﬁcation of Diseases, 9th revision, CIDI-SF = Michigan
composite international diagnostic interview, short form, SD = standard deviation, IVD = intravenous drug use, HCV = hepatitis C virus, NA = not applicable.
*
Variables used in validation of derived latent classes.
†
Deﬁned as born on or before December 31, 1955 (i.e., aged 18 or older at the last draft in 1973).
‡
Has at least one ICD-9-CM diagnosis within each of the medical and psychiatric disease clusters (i.e., multimorbidity).
+
Deﬁned as >4 on AUDIT-C score.

past and recent histories of homelessness. Alcohol use was
similarly high across HIV status. Drug use was reported by
HIV-infected and uninfected participants, with a signiﬁcantly
higher prevalence (p < .0001 for all indicators) among the former.
Self-reported drug use was higher than that captured by ICD9 diagnoses (Fig. 1) and other drug abuse/dependence criteria
(Table 1).
3.2. Latent classes based on drug use indicators: overall
For the full sample (N = 6351), a ﬁve class unadjusted model provided the best ﬁt to the observed data (entropy 5 class = 0.94, BIC
5 class = 39472.3 versus BIC 4 class = 40126.5) and deﬁned clinically interpretable and relevant subgroups labeled for convenience
based on their proﬁles of response to the latent class indica-

tors as non-users, past primarily marijuana users, past multidrug
users, current high consequence multidrug users, and current low
consequence primarily marijuana users. Local independence was
checked by looking at bivariate residuals conditional on class membership associated with each pair of drug use indicators. p-Values
associated with these tests remained below critical values for
the stratiﬁed HIV positive model and two violations were found
with critical values ﬂagging a signiﬁcant dependence in the HIV
negative model. To account for these few large residuals, direct
effects were tested between the indicators (cocaine/stimulate use,
heroin/opiate use and drug use consequences). Inclusion of the
direct effects did not further improve model ﬁt or signiﬁcantly
change the estimated model parameters or probabilities so they
were not retained in the ﬁnal models. HIV status strongly inﬂuenced
class membership, evidenced by signiﬁcantly improved model ﬁt
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Fig. 1. Latent class indicators of drug use among HIV-infected and uninfected VACS participants (n = 6351)*.
Those who indicated ‘not past year use’ for problematic drug use may or may not have experienced problems in the past with their drug use.

(2 difference = 279.56, degrees of freedom = 4, p < .0001). HIV status signiﬁcantly (p < .001) differentiated 18 of the 20 possible class
membership combinations (ﬁve comparisons, k-1 classes). Compared to non-users (reference group), HIV-infected subjects were
more likely to be classiﬁed as past multidrug users (OR 2.3), current multidrug users (OR 2.4) or, most likely, as current primarily
marijuana users (OR 3.3, all p < .0001).
3.3. HIV-speciﬁc LCAs
Based on these strong HIV effects, we conducted unadjusted
LCAs stratiﬁed by HIV status, and found that the 5 class model
again ﬁt best (HIV-infected: BIC 5 class = 21215.3 versus BIC 4
class = 21463.2; HIV uninfected: BIC 5 class = 21215.3 versus BIC
4 class = 21463.2). When the resultant classes were treated as
outcomes in bivariate and multivariable analyses, 19 candidate
covariates were identiﬁed for consideration in adjusted LCA
models. In ﬁtting the multinomial regressions, we detected nonlinearity in effects for age, anticipated from known relationships
between aging and drug use and possible generational effects
(Rosenberg, 1995; Schlaerth, 2007). At age 60, probability of membership in a current drug use class was 0.19 for the HIV-infected
and 0.087 for the HIV-infected; at age 70 these probabilities were
0.066 and 0.032, respectively.
In the ﬁnal latent class regression modeling step, adjusting
the LCA models retained the underlying structures of the unadjusted models, improved model ﬁt, and maintained high entropy
(HIV-infected: entropy = .92, BIC 5 class = 17035.4; HIV uninfected:
entropy = 0.93, BIC 5 class = 15258.5). While the item-response
probability proﬁles were similar by HIV status for the non-users and
past multidrug user classes, they differed by HIV status for past primarily marijuana and all current user classes (Table 2). Compared to
the HIV uninfected, the probability of reporting high consequence
drug use was lower for the HIV-infected current multidrug users
(0.64 HIV+ versus 0.74 HIV−). For the low consequence primarily marijuana use class, HIV-infected participants were more likely
to have a history of cocaine/stimulant use (0.43 HIV+ versus 0.32
HIV−) whereas the HIV uninfected were more likely non-users of
cocaine/stimulants (0.47 HIV− versus 0.35 HIV+).

3.4. Construct validity
3.4.1. Agreement of LCA classes and clinical diagnoses. For both HIVinfected and uninfected, Kappa statistics were moderately high
between the high consequence multidrug users and drug dependence according to CIDI (K = 0.55 HIV+, K = 0.68 HIV−) and ICD-9
(K = 0.45 HIV+, K = 0.59 HIV−). Lower bounds of the Kappa statistics for all measures of agreement lay above the suggested 0.40
minimum (Landis and Koch, 1977; Sim and Wright, 2005). The
remaining classes had small and negative Kappas with the two
drug dependence criteria. Regardless of HIV status, the non-user
class had the most negative Kappas (range: −0.32 to −0.18) with
the drug dependence criteria. Negative Kappas mean agreement
occurred less often than predicted by chance, suggesting genuine
disagreement (Juurlink and Detsky, 2005), which is expected in the
non-use and low drug use categories. Most members of the current
multidrug users class exhibited abuse/dependence criteria, regardless of HIV status, though this was consistently lower among the
HIV-infected. In sum, results suggest construct validity of the latent
classes was achieved.
3.5. Class descriptions
Table 3 displays socio-demographic and health status characteristics of the adjusted drug classes by HIV status. Hispanic/other
ethnicity, sex (HIV-infected) and education level (HIV uninfected)
were not different across classes. Health status variables not statistically signiﬁcant across class were BMI categories for overweight
and underweight, renal disease, pulmonary disease, and, for the
HIV uninfected, the medical disease cluster. For HIV-infected participants, vascular disease prevalence did not differ by class. All
other variables reported were statistically signiﬁcant across classes
by Wald tests using a Bonferroni-adjusted p-value of 0.0013. Class
descriptions below summarize ﬁndings reported in Tables 2–4 but
focus on drug use and health status results only, in the interest of
space.
3.5.1. Class 1: non-users (VACS prevalence: 36.4% HIV−, 19.6% HIV+).
Measures of mental quality of life were generally high for non-

0
0
0.93
0.06
0.35
0.43
0.20
0.01
0.72
0.21
0.06
0.03
0.04
0.53
0.40
0
0
0.88
0.12
0.47
0.32
0.19
0.02
0.68
0.16
0.15
0.09
0.09
0.49
0.33
0
0
0.36
0.64
0.03
0.16
0.45
0.35
0.41
0.23
0.35
0.09
0.43
0.32
0.16
0
0
0.26
0.74
0.04
0.18
0.40
0.38
0.38
0.24
0.37
0.10
0.44
0.31
0.14
0
0.94
0
0.06
0.02
0.98
0
0
0.11
0.89
0
0.04
0.96
0
0
0
0.94
0
0.06
0.06
0.94
0
0
0.24
0.76
0
0.08
0.92
0
0
0
0.97
0
0.03
0.57
0.43
0
0
0.96
0.04
0
0.03
0.97
0
0
0
0.98
0
0.02
0.81
0.19
0
0
0.98
0.01
0
0
1
0
0
1
0
0
0
1
0
0
0
1
0
0
1
0
0
0
0.99
0
0
0.006
1
0
0
0
1
0
0
1
0
0
0
Marijuana use

Heroin/opiate use

Cocaine/stimulant use

Never use
Past use (no/problems)
Past year use, no problems
Past year use, problems
Never
Not past year
Some past year
Heavy past year
Never
Not past year
Any past year
Never
Not past year
Some past year
Heavy past year
Problematic drug use

HIV+

19.0

HIV−

12.0

HIV+

25.5

HIV−

20.1
19.1

18.0

HIV+
HIV−

14.5
19.6

15.8

HIV−
HIV+
HIV−

36.4
Class prevalence (%)

Class 1
Non-users

Table 2
Item-response probabilities for the adjusted LCA with covariates model.

Class 2
Past primarily
marijuana

HIV+

Class 4
High consequence
multidrug
Class 3
Past multidrug

Class 5
Low consequence,
primarily marijuana
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users, while for the HIV uninfected, the median physical composite
score suggested a lower quality of life. Obesity in this class was
the second highest at 15.7% of the HIV-infected and 42.0% of the
HIV uninfected. Past year alcohol use was common but AUDIT-C
scores were low and, as expected, non-users had a low prevalence
of substance abuse or mental health treatment. Non-users had high
prevalences of chronic medical disease (i.e., diabetes, hypertension
and vascular disease) and the lowest prevalence of psychiatric diseases of all classes. HCV was relatively low for HIV-infected and
uninfected non-users. Compared to all other classes, HIV-infected
subjects in this class experienced the fewest AIDS-associated illnesses.
3.5.2. Class 2: past primarily marijuana users (VACS prevalence: 14.5%
HIV−, 15.8% HIV+). The prevalence of this class was similar by HIV
status. Past primarily marijuana users shared similar characteristics with the non-user class, regardless of HIV status. Differences
were primarily socio-demographic (more non-minorities, higher
educational status among HIV+; highest income and employment).
Additionally, past primarily marijuana users more often reported
more past year alcohol use although their AUDIT-C scores were similar to those of non-users. Medical but not psychiatric diseases were
less prevalent than in non-users. The HIV-infected had a higher
prevalence of AIDS-associated illnesses than in non-users but this
prevalence was low relative to other classes with drug use histories.
3.5.3. Class 3: past multidrug users (VACS prevalence: 19.1% HIV−,
20.1% HIV+). Overall prevalence of this class was similar by HIV
status, but the populations reported different health and drug use
experiences. A history of injection drug use was common among
the past multidrug users, more so among the HIV-infected. Past
multidrug users had the lowest reported alcohol use of all classes
but there were higher AUDIT-C scores among those continuing to
drink. This class also reported more recent treatment for substance
abuse and mental health problems than classes 1, 2 and 5. Past multidrug users suffered from signiﬁcant health problems, reﬂected in
low SF-12 physical and mental scores. The highest prevalences of
obesity and medical diseases were found in this class. Among the
HIV-infected, chronic medical diseases (i.e., diabetes, hypertension,
vascular disease) and HCV peaked in this class.
3.5.4. Class 4: high consequence, multidrug users (VACS prevalence:
18.0% HIV−, 25.5% HIV+). History of and current drug injection
distinguished this class, with current injection more common
among the HIV-infected. Evidence suggested that some members of this class transitioned from injecting to non-injecting drug
use (42.3% ever to 19.8% past year HIV−, 57.9% ever to 27.1%
past year HIV+), though available data cannot discern when such
changes took place. Continued drug use was primarily through
smoking marijuana and non-injection use of heroin/opioids and
cocaine (including crack). Class members also reported current
problem drinking. History of recent substance abuse treatment and
methadone treatment was greater in this than for all other classes
and they reported poor quality of life scores. Prevalence of obesity
was low as were medical diseases associated with obesity, especially diabetes, hypertension, and vascular disease (HIV− only). On
the other hand, prevalence of HCV and psychiatric diagnoses—in
particular, major depression and bipolar—was high. Co-occurrence
of medical and psychiatric disease (i.e., multimorbidity) and AIDSassociated illness was highest in this class.
3.5.5. Class 5: low consequence, primarily marijuana (VACS prevalence: 12.0% HIV−, 19.0% HIV+). The distinct differences by disease
status in this class were notable. Among the HIV-infected in this
class, socio-demographics (e.g., non-minority, educational status,
income, and stability) and low AUDIT-C scores were similar to
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Table 3
Characteristics of each of the ﬁve covariate-adjusted latent classes by HIV status.
Non-users

Class 1

Past primarily marijuana

Past multidrug

Class 2

Class 3

High consequence, multidrug

Class 4

Low consequence,
primarily marijuana
Class 5

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

Class prevalence (%)

36.4

19.6

14.5

15.8

19.1

20.1

18.0

25.5

12.0

19.0

Age <40
41–50
51–60
>60
Vietnam era cohort+
Female‡
Race African American
Hispanic/other†‡

15.0
25.8
33.5
25.7
69.6
11.7
54.5
14.2

20.6
30.4
28.0
21.0
57.3
2.6
64.6
12.3

20.6
31.3
35.8
12.3
58.1
9.2
56.2
15.0

17.6
35.2
35.7
11.5
56.6
2.1
54.5
11.7

4.6
44.9
44.3
6.2
68.1
6.6
63.0
15.0

3.3
43.2
46.9
6.6
70.8
2.4
66.6
16.0

8.0
58.2
31.3
2.5
50.1
2.5
79.6
9.1

7.3
51.1
37.3
4.3
57.8
2.8
80.4
10.4

14.6
33.7
40.3
11.4
62.3
4.7
56.4
13.7

18.5
40.6
34.5
6.4
53.2
2.3
53.0
15.4

Married/living with partner
Education < high school†
Income >$25,000

47.2
38.8
42.8

24.4
35.7
31.0

45.0
37.8
45.3

23.2
33.9
34.3

36.8
38.6
28.0

25.5
42.8
20.7

21.6
46.0
13.0

13.9
49.9
10.9

39.8
42.4
31.0

28.8
31.6
28.3

IVD past year
Ever IVD
Last injection heroin
Last injection cocaine

0.6
3.0
0.8
0.3

0.8
8.3
2.6
1.7

0
0.5
0
0

0.7
2.1
0.2
0.5

2.9
31.3
8.2
6.6

2.2
66.0
20.5
18.4

19.8
42.3
22.5
12.4

27.1
57.9
30.9
22.8

1.2
10.8
3.2
2.6

0.8
21.0
4.5
5.5

Past month worry about food
Ever homeless
Homelessness, past month

15.3
19.6
2.9

14.0
26.6
2.3

14.3
20.1
2.4

19.2
27.2
3

23.8
61.0
11.7

22.3
62.7
3.7

40.6
83.1
40.0

39.5
77.6
22.1

27.2
45.3
6.4

22.6
35.1
2.7

56.1
28.4
58.6
1 (3)

68.3
31.5
74.6
2 (3)

69.5
38.7
74.6
2 (2)

85.0
53.7
46.3
2 (4)

90.6
55.5
38.9
2 (4)

89.1
77.1
83.9
3 (6)

91.4
81.6
80.8
3 (5)

79.2
51.5
79.2
3 (4)

76.4
49.5
84.0
2 (3)

Concurrent substance use, mental health, and treatment (%)
Ever smoked
58.5
Smokes currently
25.4
61.3
Alcohol use*
AUDIT-C score, median (IQR)
1 (3)
Substance abuse treatment*
Methadone maintenance treatment*

3.0
0.3

3.6
1.1

2.9
0%

2.3
0.2

19.6
5.1

15.5
6.6

60.0
20.8

39.2
11.6

3.5
0.3

0.4
0

Psychiatric disease cluster
Schizophrenia
Major depression, bipolar
Post traumatic stress disorder

17.6
5.0
9.9
8.2

13.6
2.6
11.1
4.3

17.9
4.1
9.9
7.7

14.3
1.2
11.7
3.8

36.3
7.9
22.7
17.9

30.3
6.1
18.3
12.7

46.6
10.1
35.2
21.0

34.8
6.7
27.1
11.0

25.1
5.3
16.7
11.4

19.3
1.7
14.8
4.5

SF-12 Mental composite, median (IQR)
Mental health treatment*

53.6 (15.3)
21.4

52.1 (15.5)
19.1

55.3 (14.5)
22.8

51.5 (17.7)
19.9

47.5 (20.2)
45.0

48.6 (16.7)
33.8

41.5 (18.8)
73.2

43.6 (18.0)
45.6

48.8 (18.9)
29.5

45.9 (18.7)
21.0

42.0
37.5
1.2

15.7
38.0
4.2

41.0
41.2
1.2

11.3
42.0
2.8

43.5
33.3
0.9

20.1
37.1
2.6

32.0
37.8
1.9

9.4
33.8
4.1

37.7
36.0
1.5

8.8
34.9
5.1

Physical and medical conditions (%)
BMI categories Obese
Overweight†‡
Underweight†‡
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HIV−

IVD = intravenous drug use, IQR = interquartile range, AUDIT-C = alcohol use disorders identiﬁcation test-consumption, SF-12 = short form 12, BMI = body mass index, HCV = hepatitis C virus. Medical & psychiatric cluster means
that the participant has at least one ICD-9-CM diagnosis within each of the medical and psychiatric disease clusters (i.e., multimorbidity).
Equality tests of means across classes using posterior-probability-based multiple imputations with 4 degrees of freedom.
Bonferroni-adjusted p-value: 0.0013. Unless noted as below, equality tests of means were statistically signiﬁcant.
+
Deﬁned as born on or before December 31, 1955 (i.e., aged 18 or older at the last draft in 1973).
*
Past year.
†
Equality tests of means not statistically signiﬁcant (>0.0013) for HIV uninfected group.
‡
Equality tests of means not statistically signiﬁcant (>0.0013) for HIV-infected group.

45.4 (19.2)
21.2
40.8 (18.2)
–
40.6 (16.5)
26.3
41.9 (18.0)
20.1
40.9 (20.2)
–
44.2 (19.2)
–
SF-12 Physical composite, median (IQR)
AIDS-associated illness*

47.4 (17.8)
18.9

47.5 (18.2)
–

46.1 (17.9)
23.0

48.4
69.3
14.6
46.6
1.2
13.4
9.9
34.2
69.9
75.6
16.6
33.2
4.4
11.2
9.2
24.2

41.3 (18.6)
–

HIV+

32.2
48.7
8.8
24.2
3.5
8.8
7.2
12.5
22.8
69.3
20.2
53.2
2.6
10.8
16.4
17.0

HIV−
HIV−
HIV+

38.1
75.6
25.5
52.2
2.6
13.7
12.8
28.7
23.5
43.9
10.8
26.1
2.1
6.8
4.7
6.3

HIV+
HIV+

9.7
63.4
19.6
53.0
2.4
8.7
13.1
13.1

HIV−
HIV−

27.6
54.6
15.5
33.8
3.8
8.3
9.4
9.4

Class 2
Class 1

11.8
71.1
27.3
59.7
3.8
10.7
18.1
13.6

Past primarily marijuana
Non-users

HCV positive
Medical disease cluster†
Diabetes
Hypertension
Renal disease†‡
Pulmonary disease†‡
Vascular disease‡
Medical & psychiatric cluster

Table 3 (Continued )

67.2
65.5
9.7
29.6
3.5
9.4
7.4
25.5

HIV−

HIV+
Class 4
Class 3

Class 5

High consequence, multidrug
Past multidrug

Low consequence,
primarily marijuana
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prevalences reported for class 1 and 2. For the HIV uninfected,
socio-demographics (e.g., employment, history of homelessness,
educational status) and high AUDIT-C scores were more akin to
those of multidrug users (class 3, 4). Past year alcohol use was
reported by approximately 80% of this class and, generally, members were less likely to have been treated recently for substance
abuse.
Regarding health status, the HIV-infected in class 5 had the lowest prevalence of obesity and a (non signiﬁcant) high prevalence
of being underweight. In contrast, prevalence of obesity was similar among the HIV uninfected in this class to those not currently
using drugs. The HIV uninfected had lower physical than mental
quality of life composite scores. Regardless of HIV status, class 5
exhibited poor quality of life on the SF-12 mental composite akin
to current multidrug users yet unlike them receipt of mental health
treatment was low. Medical and psychiatric disease prevalence in
the HIV uninfected fell between those of classes 1, 2 and of 3, 4. A
lower prevalence of AIDS-associated illness and medical and psychiatric disease was associated with this class’s HIV-infected, in line
with or lower than classes of users without a history of multidrug
use.
Taken together, the Tables 2 and 3 data suggested that, more
than a year ago, some of class 5 members transitioned away from
hard drug use (i.e., HIV−, HIV+: 0.16, 0.21 probability of past
heroin/opioid, 0.32, 0.43 past cocaine/stimulant) and injecting (i.e.,
1.2%, 0.8% current injecting, 10.8%, 21.0% history of injecting) to primarily marijuana use. Other responses (e.g., never use) suggested
initiation or continued use of primarily marijuana.
4. Discussion
This study used LCA to discover subpopulations of drug users
and latent class regression to explicitly incorporate the inﬂuence
of HIV status on their composition. We observed considerable drug
use among an older adult population, one which is often not recognized as HIV-infected or drug using (Bhavan et al., 2008; Effros et al.,
2008; Goulet et al., 2007; Hartel et al., 2006). A table in the online
Appendix A1 summarizes the ﬁndings including similarities among
classes, distinguishing characteristics, and HIV-speciﬁc results.
The continued drug use and speciﬁc patterns detected in our
sample extend ﬁndings reported from other studies of aging, drug
use, and HIV (Hartel et al., 2006; Hser et al., 2001; Lieberman, 2000;
Pitts et al., 2005; Rosenberg, 1995; Schlaerth, 2007; Schlaerth et al.,
2004). Similarities in drug use of HIV-infected and uninfected populations exist, suggesting that the general medicine clinic controls
match well to the HIV-infected. However, key differences by HIV
status emerged from this analysis, with clinical and public health
implications for HIV and aging populations.
We found that drug use and abuse were lower but not uncommon among those of older ages, with illness, or even with HIV.
These ﬁndings reinforce the need for age-appropriate treatment
and harm reduction services and for physicians and caregivers to
continue screening for substance abuse and dependence, regardless
of their patient’s age or disease status. Health maintenance guidelines for geriatric care (e.g., http://www.americangeriatrics.org)
and for people aging with HIV make limited mention of substance
abuse screening (Bhavan et al., 2008).
Within the HIV-infected and uninfected in the VACS, psychiatric comorbidities, medical comorbidities, and their co-occurrence
were more prevalent in people with current and past histories of
multidrug use but were far less prevalent among current primarily
marijuana users. The “multimorbidity” among Veterans with HIV

1
Appendix – A summary of results is available as a table with the online version
of this article at doi:10.1016/j.drugalcdep.2010.02.020.
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Table 4
Variables independently associated with class membership, latent class analysis with covariates results stratiﬁed by HIV status (reference = Class 1, non-users).
Past multidrug
Class 3

High consequence, multidrug
Class 4

Low consequence, primarily marijuana
Class 5

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

HIV−

HIV+

1.14
(0.78, 1.65)
0.76
(0.55, 1.04)
0.29
(0.18, 0.45)

0.74
(0.49, 1.11)
1.07
(0.75, 1.53)
0.38
(0.24, 0.61)

0.41
(0.24, 0.70)
0.60
(0.44, 0.82)
0.18
(0.11, 0.30)

0.28
(0.14, 0.54)
0.85
(0.59, 1.21)
0.33
(0.18, 0.59)

0.49
(0.29, 0.85)
0.31
(0.19, 0.50)
0.11
(0.03, 0.37)

0.54
(0.32, 0.90)
0.60
(0.40, 0.90)
0.25
(0.12, 0.51)

1.45
(0.72, 1.81)
0.79
(0.55, 1.13)
0.36
(0.21, 0.61)

0.76
(0.52, 1.12)
0.82
(0.58, 1.15)
0.21
(0.12, 0.36)

1.11
(0.83, 1.49)
1.00
(0.66, 1.50)

0.53
(0.38, 0.74)
0.59
(0.36, 0.97)

1.30
(0.94, 1.80)
1.20
(0.78, 1.85)

1.13
(0.73, 1.76)
1.36
(0.78, 2.36)

2.90
(1.62, 5.19)
1.22
(0.57, 2.63)

3.06
(1.59, 5.90)
1.91
(0.91, 4.03)

1.09
(0.77, 1.54)
0.87
(0.54, 1.40)

0.63
(0.45, 0.88)
0.83
(0.52, 1.34)

Currently employed

0.82
(0.62, 1.08)

0.98
(0.71, 1.34)

0.98
(0.70, 1.31)

0.85
(0.59, 1.21)

0.51
(0.33, 0.79)

0.47
(0.32, 0.71)

0.60
(0.44, 0.83)

0.72
(0.52, 0.99)

Alcohol use past year

1.51
(1.10, 2.06)
1.04
(0.97, 1.11)

2.06
(1.44, 2.96)
1.03
(0.95, 1.12)

0.52
(0.37, 0.73)
1.13
(1.06, 1.20)

0.52
(0.35, 0.77)
1.18
(1.09, 1.27)

3.16
(1.86, 5.39)
1.16
(1.07, 1.25)

2.99
(1.91, 4.70)
1.20
(1.10, 1.30)

1.87
(1.30, 2.70)
1.13
(1.06, 1.21)

3.65
(2.55, 5.22)
1.08
(1.01, 1.15)

1.92
(1.39, 2.66)
0.84
(0.61, 1.16)

1.93
(1.34, 2.79)
1.00
(0.69, 1.44)

2.56
(1.73, 3.80)
1.12
(0.82, 1.53)

2.85
(1.78, 4.57)
1.59
(1.08, 2.33)

1.66
(0.90, 3.07)
1.82
(1.10, 2.99)

1.57
(0.84, 2.94)
3.57
(2.20, 5.81)

1.92
(1.29, 2.86)
1.45
(1.01, 2.07)

2.13
(1.46, 3.10)
1.27
(0.88, 1.82)

Ever homeless

1.18 (0.80,1.72)

Past mo homeless

0.81
(0.36, 1.81)
0.87
(0.58, 1.31)

0.89
(0.61, 1.28)
1.48
(0.57, 3.89)
1.49
(1.00, 2.22)

2.96
(2.19, 4.01)
1.29
(0.74, 2.23)
0.89a
(0.61, 1.32)

2.21
(1.56, 3.11)
0.78
(0.33, 1.85)
1.17
(0.78, 1.75)

4.22
(2.66, 6.71)
2.86
(1.58, 5.17)
1.32
(0.85, 2.06)

3.36
(2.02, 5.61)
2.81
(1.27, 6.21)
1.82
(1.19, 2.78)

2.58
(1.84, 3.65)
0.65
(0.31, 1.35)
1.16
(0.80, 1.68)

1.11
(0.81, 1.52)
1.03
(0.37, 2.85)
1.38
(0.94, 2.03)

0.30
(0.002, 47.42)
0.16
(0.02, 1.33)

1.46
(0.31, 6.76)
0.39
(0.14, 1.05)

1.37
(0.51, 3.70)
7.61
(4.57, 12.65)

0.59
(0.16, 2.10)
11.61
(7.66, 17.59)

7.67
(2.96, 19.84)
9.43
(4.99, 17.80)

12.26
(3.68, 40.87)
7.29
(4.35, 12.24)

1.40
(0.36, 5.42)
2.72
(1.50, 4.93)

0.53
(0.11, 2.51)
2.94
(1.88, 4.57)

SF-12 mental composite score

1.01
(0.99, 1.02)

1.00
(0.99, 1.02)

0.99
(0.98, 1.00)

0.99
(0.97, 1.01)

0.97
(0.96, 0.99)

0.99
(0.97, 1.00)

0.99
(0.97, 1.00)

0.98
(0.97, 0.99)

Past year SA treatment

1.14 (0.52, 2.47)

0.66 (0.21, 2.11)

3.75 (2.23, 6.30)

2.18 (1.12, 4.23)

17.91 (9.91, 32.39)

5.55 (2.80, 11.00)

0.98 (0.39, 2.46)

0.18 (0.04, 0.92)

BMI (ref = normal) Obese

–

–

Underweight

–

0.63
(0.38, 1.05)
0.78
(0.54, 1.15)
0.57
(0.21, 1.61)

–

–

1.54
(0.98, 2.41)
1.07
(0.75, 1.52)
0.68
(0.31, 1.53)

–

Overweight

0.70
(0.45, 1.11)
1.12
(0.83, 1.52)
0.62
(0.27, 1.41)

0.47
(0.30, 0.74)
0.81
(0.60, 1.09)
0.90
(0.42, 1.93)

Married

–

Sex (1 = female)

0.64
(0.41, 1.00)

Age (ref = 41–50) <40
51–60
>60
African American
Hispanic/other

AUDIT-C score
Ever smoked
Smokes currently

Past mo worry about food
IVD past yr
Ever IVD

0.83
(0.59, 1.15)
–

–
–
–
0.55
(0.34, 0.91)

0.77
(0.53, 1.13)
–

–
–
–
0.18
(0.07, 0.46)

0.48
(0.31, 0.75)
–

–
–
–
0.37
(0.20, 0.68)

Adjusted odds ratios and (95% conﬁdence intervals). Reference class = non-users, Class 1.
Model is adjusted for all other signiﬁcant covariates detected in multinomial regressions using the unadjusted LCA class results.
– = no estimate because variable not included in model.
SA = substance abuse, including alcohol and/or drug abuse, BMI = body mass index, IVD = intravenous drug use, AUDIT-C = alcohol use disorders identiﬁcation test-consumption, SF-12 = short form 12.
Bold values are statistically signiﬁcant from the reference non-user class within HIV status.

1.04
(0.76, 1.43)
–
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Past, primarily marijuana
Class 2
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and substance use disorder has been described previously (Goulet
et al., 2007). Our results expand upon this work by highlighting
the heterogeneity and range of multimorbidity by pattern of drug
use. This study did not capture severity of comorbidities, however, for similar prevalences of medical and psychiatric comorbidity
diagnoses, members of the current multidrug users class reported
the lowest physical and mental quality of life scores. In addition,
AIDS-associated illness was highest in the current multidrug users
class. Results suggest that effectively treating the older adult HIVinfected patient in the VA, as elsewhere, will entail addressing
multimorbidities as well as employing special efforts such as interventions to improve medication adherence and reduce depressive
symptoms (Altice et al., 2007, 2004; Safren et al., 2009), to keep
AIDS-associated illness at bay in older adults who continue multidrug use.
The low consequence, primarily marijuana users appear to be a
unique drug-using group. The low prevalence of drug dependence
and the absence of negative consequences despite chronic use runs
counter to research on cannabis abuse/dependence and their subtypes (Grant et al., 2006). However, other LCA studies have detected
the existence of a marijuana-only drug use class amongst nationally
representative samples of lifetime drug users (Agrawal et al., 2007).
Motivations for primarily marijuana use may be a mixture of transitions away from use of other drugs, (re)initiation, self-medication,
or evidence of diffusion of medical marijuana as innovative treatment (e.g., appetite stimulation, management of medication side
effects (de Jong et al., 2005; Haney et al., 2007; Kuo et al., 2004)),
which might be better known to the HIV community and their
physicians. Whether this class represents a later stage of drug use,
as suggested by similarities to the multidrug user classes for the
HIV uninfected, a therapeutic disease-speciﬁc class, as suggested
by similarities to the non-user and past marijuana users for the
HIV-infected, or if differences indicate two separate pathways into
this class, is open for inquiry.
The discovered classes appear to be valid, as indicated by the
association between the clinical diagnostic criteria in the expected
directions and by the covariates predictive of class membership.
For example, one would have expected, as was found, that recent
injecting drug use would be strongly related to the high consequence, multidrug users (class 4) but not to any other class.
Adjusting for covariates improved our models’ ﬁt, aligning results
closer to the true class membership and highlighting the interplay of predisposing (e.g., race, gender, homelessness), enabling
(e.g., income, education), and need (e.g., comorbidities) factors
expected under Gelberg’s Behavioral Model for Vulnerable Populations (Gelberg et al., 2000). Other reported LCAs of drug abuse
(e.g., (Agrawal et al., 2007; Monga et al., 2007) have not adjusted
for covariates.
Some of our ﬁndings concur with previously reported LCAs,
which detected classes of marijuana-only and multidrug users
(Agrawal et al., 2007), while there are also some classes we could
not detect, such as prescription drug abusers. Differences may be
explained by choice of study sample (age, illness status), exposure assessment (lifetime versus past year use, types of drugs
assessed), choice of model (dichotomous, ordinal, etc.), and inclusion of covariates, among others.
Future studies should explore longitudinal transitions between
classes and test hypotheses about class membership. Little is
known about how frequently older HIV-infected and uninfected
drug users move in and out of treatment, initiate and terminate
drug use, and switch to other substances (Hser et al., 2007). It
has been hypothesized that the increasing isolation experienced
as one ages may promote transitions from “harder” drugs (e.g.,
heroin) which may be used alone to “softer” drugs (e.g., marijuana)
used more socially (Fogarty et al., 2007; Osborne and Fogel, 2008;
Schlaerth et al., 2004). Future endeavors should also test the utility

217

and validity of our derived drug use classes in predicting key health
outcomes.
This study has several limitations. The crucial limitation is its
cross-sectional nature. One cannot conclude from our data, for
example, that drug use decreases with increasing age but rather
that, at the ages represented in VACS, probability of certain class
membership is lower at older ages. In cross-sectional designs, it
is also not possible to determine whether the classes of current
and past drug users are stable or dynamic, whether they represent
switching of substances or harm minimizing use, intensiﬁcation
or diminution of particular substances used over time, or whether
members are incident, chronic prevalent or relapse case members.
Longitudinal analyses are underway to address such questions. In
the meantime, this study presents hypothesis-generating, initial
descriptions and comparisons by HIV status of an aging, considerably active drug-using population. Also, VACS focuses on an aging
population, thus our study may not be representative of young HIVinfected Veterans and women, who could have different drug use
patterns. The largely male older Veteran population of the VACS
may also not be representative of aging adults more generally.
However, drug use in older adults occurs predominantly among
males (Armstrong, 2007; Han et al., 2009a; Zanjani et al., 2007)
and the high degree of drug use found in the VACS HIV uninfected
population shares similarities with use among older people in the
general population described by others (Han et al., 2009b). Prevalence of club drug and benzodiazepine use was not assessed, hence
we may have underestimated the true prevalence of drug use. Prescription opioid abuse was not measured separately from heroin so
any potential transition to these substances would not be detected
in item-response probabilities. Finally, the extent to which our ﬁndings generalize to non-Veterans is unknown. While Veterans in
care generally differ substantially from the US population receiving
health care, Veterans in care with HIV infection have much in common with others receiving treatment for HIV infection (Conigliaro
et al., 2006; Kohli et al., 2005; Lohse et al., 2007; Palella et al., 2006).
As evidence of this fact, VACS data was directly compared to other
large HIV cohorts in Europe and North America and deemed consistent enough with these other samples to be combined in two
high proﬁle cross cohort analyses (Kitahata et al., 2009; Sterne et
al., 2009).
The prevalence of any current drug use (classes 4 and 5) in
the VACS was 44.5% among HIV-infected and 30% among HIV
uninfected. Relying on clinical reports of drug dependence would
instead place the estimate at 25% (ICD-9 code) or 14% (CIDI-SF), with
no statistical differences by HIV status. Moreover, there was substantial divergence between EMR and self-reported data (CIDI-SF
or LCA) for the past multidrug user class, implying misclassiﬁcation
of past users as current users in the EMR. An LCA approach to exposure measurement serves as a descriptive and analytic tool to ﬁnd
consensus in patterns of behavior reported by participants in a way
that incorporates rather than punishes for measurement error and
missing data typical in observational study. As the application of
LCA continues to expand (Muthen, 1992, 2008), our study suggests
that LCA can be used to detect statistically and clinically valid subpopulations of drug users without having to administer lengthy
interviews or having to rely solely on medical record-generated
proxies of drug abuse/dependence.
Our ﬁndings contribute to the increasing literature on drug use,
aging, and HIV (Bhavan et al., 2008; Effros et al., 2008; Ettenhofer
et al., 2009; Han et al., 2009a,b) and are directly relevant to
the VA, which provides treatment and care to more than 19,000
people with HIV and 213,000 people diagnosed with Substance
Abuse Disorders as well as to Veterans with undetected diagnoses.
Speciﬁcally, intervention should be prioritized for the problematic
multidrug user class, who showed considerable need, poor health,
and low quality of life. Results lend support for efforts to inte-

218

T.C. Green et al. / Drug and Alcohol Dependence 110 (2010) 208–220

grate mental health, chronic disease, and HIV care; implementation
of screening for improved detection of drug abuse and potential referral for specialized care; and expansion of age-appropriate
treatment and harm reduction options for drug users.
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